According to Towards Healthcare research, the recombinant proteins market size is estimated at USD 3.05 billion in 2024, growing to USD 3.36 billion in 2025, and is projected to reach approximately USD 8.08 billion by 2034.
The market is experiencing strong growth due to the increasing prevalence of fatal diseases such as cancer, cardiovascular issues, and basic health problems observed due to an improper lifestyle. The high demand for recombinant proteins in various industries, such as medical, research, and food and beverage, has also contributed to the market's growth in recent periods.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5435
Key Highlights of the Recombinant Proteins Market
• By region, North America led the recombinant proteins market in 2024, whereas Asia Pacific is expected to be the fastest-growing region in the forecast period.
• By product, the cytokines and growth factors segment led the market in 2024, whereas the antibodies segment is expected to grow in the expected timeframe.
• By application, the therapeutics segment led the market for recombinant proteins in 2024, whereas the drug discovery and development segment is expected to grow in the foreseeable period.
• By end-user, the pharma and biotechnology companies segment led the recombinant proteins sector, whereas the academic and research institutes segment is expected to grow in the expected timeframe.
• By host cell, the mammalian cell segment led the recombinant proteins market in 2024, whereas the bacterial cell segment is expected to grow in the forecast period.
Market Overview
The procedure of developing recombinant proteins involves combining two DNA sequences that rarely occur naturally, necessitating experimentation and artificially recombining proteins. Situations such as high protein yields, free of animal contaminants, and regulated batch-to-batch fluctuation are all possible in the case of recombinant protein synthesis. The production of certain required proteins on a large scale is possible with the help of recombinant protein manufacturing, which is helpful in the growth of the recombinant proteins market.
The technologically advanced procedure starts at the genetic level and eventually involves steps such as transferring the desired gene to the appropriate host for gene expression, transcription, and mRNA translation into proteins. High demand for advanced technology in various fields such as the food and beverage industry, medical, and research is helping to boost the growth of the market.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
New Trends in the Recombinant Proteins Market
• The rising prevalence of chronic diseases such as cancer, heart issues, and diabetes is leading to high demand for protein-based therapeutics, further fueling the growth of the recombinant proteins market.
• Another major factor helpful for the growth of the market involves patent expirations for original biologics, creating opportunities for biosimilars.
• High investment in the growth and development of the market, involving the development of life sciences research, along with genetically engineered mouse models.
How has AI impacted the Recombinant Proteins Market?
Artificial intelligence has had a major role in the recombinant proteins market through the acceleration of protein discovery, improving production efficiency, and more targeted applications. Historically, developing recombinant proteins has been a time-consuming process with significant room for trial-and-error. The use of artificial intelligence has streamlined recombining proteins with predictive algorithms, model protein folding, and more, being used in the most efficient manner. These proteins have also seen wide application in drug development, where AI-driven analytics are used to isolate new protein-based therapeutics and vaccines, leading to a massive reduction in research and development costs and shortened timelines.
• In May 2025, researchers from the Indian Institute of Technology Guwahati deployed machine learning assisted media optimization for enhanced insulin production in Pseudomonas fluorescens cell factory and scale-up studies. Their study showed that optimization of process parameters and medium components is crucial in bioprocessing and leads to maximum product titer, yield, and productivity.
Market Dynamics
Driver
What Is the Major Growth Driver of the Recombinant Proteins Market?
Growing incidences of chronic illnesses such as cancer, heart issues, skin issues, and prostate problems are one of the major factors for the growth of the recombinant proteins market. Such issues highlight the necessity for a targeted and efficient protein treatment approach. The market has also observed huge growth in the recent period due to high demand for recombinant DNA technologies for effective immunotherapy. The goal of the use of advanced technology is to get rid of the dangerous tumor, along with strengthening the immune system and enhancing resistance to malignant cells.
Restraint
How Are High Costs Impacting the Growth of the Recombinant Proteins Market?
The advanced technology of using recombinant DNA technology for the production of proteins in large quantities requires investment of time, resources, and costs for various procedures. The advanced technology may also require an investment of billions of dollars, hampering the growth of the recombinant proteins market. The manufacturing of recombinant proteins requires high costs for different procedures, further fueling the costs of final therapeutic goods. Hence, the cost-conscious patients in need of such recombinant proteins may step back due to the high costs of the final products, further restraining the growth of the market.
Opportunity
High Demand for Proteins for Biotherapeutics Is Helping the Expansion of the Market
Use of biotherapeutic medications for treatment of various types of chronic illnesses, such as cancer, heart issues, skin and prostate issues, and various similar problems, provides a huge opportunity for the growth of the recombinant proteins market. Biotherapeutic medications target certain cells and tissues, which are helpful for the treatment of such illnesses, further fueling the growth of the market. Huge investments by industries such as pharmaceutical firms, life sciences research, and medical fields are also opening the gates of huge opportunities for the growth of the market.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
Segmental Analysis
Product Insights
The cytokines and growth factors segment dominated the recombinant proteins market in 2024 due to its high usage in multiple domains such as immunology, neurology, COVID-19, HIV/AIDS, and cancer. Global acceptance of cytokines for cancer treatment has further helped the growth of the market. The market is also growing internationally due to high demand for recombinant protein products for regenerative medicine.
The antibodies segment is expected to grow in the forecast period due to the high dependence of procedures such as western blotting, immunohistochemistry, and ELISA on recombinant antibodies. Their excellent sensitivity and specificity help to identify disease-related antigens and biomarkers. A combination of such factors overall helps the growth of the recombinant proteins market.
Application Insights
The therapeutics segment led the recombinant proteins market in 2024 due to the prevalence of chronic disorders such as various forms of cancer, prostate and skin issues, immunology disorders, metabolic disorders, and genetic abnormalities. The increasing importance of recombinant proteins for vaccines and cell/gene therapies also helped the growth of the market for recombinant proteins in 2024. Advancements in biologics, such as antibodies and fusion proteins, are also a vital factor for the growth of the market.
The drug discovery and development segment is expected to grow in the foreseeable period, helping the growth of the recombinant proteins market. The growth of the research and development domain, along with high investment in the sector, is further fueling the growth of the market in the forecast period. Protein therapies are also essential for treating certain illnesses such as diabetes, cancer, infectious diseases, hemophilia, and anemia.
End-User Insights
The pharma and biotechnology companies segment led the recombinant proteins market in 2024 due to high investment in research and development for expanding product pipeline, developing new technologies, and improving bioprocessing instruments. Growing consumer demand for recombinant protein products is another major factor for the growth of the recombinant proteins sector.
The academic and research institutes segment is expected to grow in the foreseen period, aiding the growth of the recombinant proteins market. High investment in the research and development sector in the form of industry-academia engagement and collaboration is also helping the growth of the market. Collaborations and partnerships are helpful for the discovery of new treatment methods for patients, and with the discovery of useful drugs, also aid the growth of the recombinant proteins industry.
Host Cell Insights
The mammalian cell segment dominated the recombinant proteins market in 2024 due to its high demand in conjunction with the growth of the proteomics and biologics sector. Protein expression systems can be easily integrated into high-throughput systems for efficient proteomics and biologics research, further fueling the market’s growth. Rising prevalence of various chronic issues, such as different forms of cancer, skin issues, and heart-related illnesses, along with high investment in the research and development sector, has also fueled the growth of the recombinant proteins market.
The bacterial cell segment is observed to grow in the foreseeable period due to the use of bacterial cells as host cells for biotechnology and research. Easy handling, well-characterized genetics, and quick growth make bacterial cells highly desirable for protein expression. Increasing demand by a variety of applications, involving drug research and antibodies, is also helping the growth of the market in the foreseeable future.
Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting
Regional Analysis
North America Dominated the Recombinant Proteins Market in 2024
North America led the recombinant proteins market share by 42% in 2024, with the US driving the growth of the market in the region. High investment in the research and development sector, easy accessibility of healthcare facilities, and rising prevalence of cancer in the region are other important factors for the growth of the market in the region in 2024. The presence of important market participants in the region also helped the growth of the recombinant proteins industry in North America. High usefulness of recombinant proteins for cancer treatment and mergers and acquisitions for drug and treatment method development are also major factors for the growth of the market.
Asia Pacific Is Expected to Grow the Fastest During the Forecast Period in the Recombinant Proteins Market
Asia Pacific is expected to rise with the highest CAGR in the forecast period, helping the growth of the recombinant proteins market. High investment by biopharmaceutical companies in the research and development sector, supportive government policies and regulations in the aging population, along with rising chronic illnesses resulting in high demand for targeted therapies, are some of the factors helping the growth of the market in the region. Improvement of proteomic and genomic research techniques in the region has also helped the growth of the market.
Recent Developments in the Recombinant Proteins Market
• In March 2025, WuXi Biologics, a China-based CRDMO, announced the launch of its proprietary E.coli expression system named ‘EffiX’, engineered to deliver high yield and stability for the production of recombinant proteins.
• In September 2024, Axio Biopharma, a provider of high-quality recombinant proteins, announced its plan to manufacture recombinant protein projects. The main aim of the launch is to meet the growing demands of the biopharmaceutical industry.
Top Companies of the Recombinant Proteins Market
• Thermo Fisher Scientific
• Merck KGaA
• Bio-Techne
• Abcam plc
• Abnova Corporation
• GenScript Biotech Corporation
• Sigma Aldrich Company
• GE Healthcare
• Prospec-Tany Technogene Ltd.
• BPS Bioscience
• RayBiotech Life Inc.
• STEMCELL Technologies Inc.
• Bio-Rad Laboratories, Inc.
• Proteintech Group, Inc.
• Sino Biological, Inc.
Segments Covered in the Report
By Product
• Cytokines & Growth Factors
Interferons (IFNs)
Interleukins (ILs)
Others
• Antibodies
• Immune checkpoint proteins
• Virus Antigens
• Enzymes
Kinases
Metabolic enzymes
Others
• Recombinant Regulatory Protein
• Hormones
• Others
By Application
• Drug Discovery & Development
• Therapeutics
Biologics
Vaccines
Cell & Gene Therapies
Others
• Research
• Others
By End Use
• Pharma & Biotechnology Companies
• Academic & Research Institutes
• Diagnostic Laboratories
• Others
By Host Cell
• Mammalian systems
• Insect Cells
• Yeast & Fungi
• Bacterial Cells
• Others
By Region
• North America
○ U.S.
○ Canada
○ Mexico
• Europe
○ Germany
○ U.K.
○ France
○ Italy
○ Spain
○ Denmark
○ Sweden
○ Norway
• Asia Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Thailand
• Latin America
○ Brazil
○ Argentina
• Middle East & Africa
○ South Africa
○ Saudi Arabia
○ U.A.E.
○ Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5435
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
